Several preclinical studies described that CDK4/6i themselves could boost antitumor immune responses in BC and other cancers, driven by T cell-intrinsic mechanisms as well as enhancement of antigen presentation in tumor cells. The gene discussed is CDK4; the disease is neoplasm.